United States - English - NLM (National Library of Medicine)

proficient rx lp - tadalafil (unii: 742sxx0ict) (tadalafil - unii:742sxx0ict) - tadalafil tablets are indicated for the treatment of erectile dysfunction (ed). tadalafil tablets are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (bph). tadalafil tablets are indicated for the treatment of ed and the signs and symptoms of bph (ed/bph). if tadalafil is used with finasteride to initiate bph treatment, such use is recommended for up to 26 weeks because the incremental benefit of tadalafil decreases from 4 weeks until 26 weeks, and the incremental benefit of tadalafil beyond 26 weeks is unknown [see clinical studies (14.3)] .  administration of tadalafil to patients who are using any form of organic nitrate, either regularly and/or intermittently, is contraindicated. in clinical pharmacology studies, tadalafil was shown to potentiate the hypotensive effect of nitrates [see clinical pharmacology (12.2)] . tadalafil is contraindicated in patients with a known serious hypersensitivity to tadalafil (tadalafil tablets or adcirca® ). hypersensitivity reactions

United States - English - NLM (National Library of Medicine)

burel pharmaceuticals, llc - tadalafil (unii: 742sxx0ict) (tadalafil - unii:742sxx0ict) - tadalafil tablets are indicated for the treatment of erectile dysfunction (ed). tadalafil tablets are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (bph). tadalafil tablets are indicated for the treatment of ed and the signs and symptoms of bph (ed/bph). if tadalafil tablets are used with finasteride to initiate bph treatment, such use is recommended for up to 26 weeks because the incremental benefit of tadalafil tablets decreases from 4 weeks until 26 weeks, and the incremental benefit of tadalafil tablets beyond 26 weeks is unknown [see clinical studies ( 14.3)] . administration of tadalafil tablets to patients who are using any form of organic nitrate, either regularly and/or intermittently, is contraindicated. in clinical pharmacology studies, tadalafil was shown to potentiate the hypotensive effect of nitrates [see clinical pharmacology (

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - tadalafil (unii: 742sxx0ict) (tadalafil - unii:742sxx0ict) - tadalafil tablets are indicated for the treatment of erectile dysfunction (ed). tadalafil tablets are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (bph). tadalafil tablets are indicated for the treatment of ed and the signs and symptoms of bph (ed/bph). if tadalafil is used with finasteride to initiate bph treatment, such use is recommended for up to 26 weeks because the incremental benefit of tadalafil decreases from 4 weeks until 26 weeks, and the incremental benefit of tadalafil beyond 26 weeks is unknown [see clinical studies (14.3)] .  administration of tadalafil to patients who are using any form of organic nitrate, either regularly and/or intermittently, is contraindicated. in clinical pharmacology studies, tadalafil was shown to potentiate the hypotensive effect of nitrates [see clinical pharmacology (12.2)] . tadalafil is contraindicated in patients with a known serious hypersensitivity to tadalafil (tadalafil tablets or adcirca® ). hypersensitivity reactions

United States - English - NLM (National Library of Medicine)

quallent pharmaceuticals health llc - tadalafil (unii: 742sxx0ict) (tadalafil - unii:742sxx0ict) - tadalafil tablets are indicated for the treatment of erectile dysfunction (ed). tadalafil tablets are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (bph). tadalafil tablets are indicated for the treatment of ed and the signs and symptoms of bph (ed/bph). if tadalafil is used with finasteride to initiate bph treatment, such use is recommended for up to 26 weeks because the incremental benefit of tadalafil decreases from 4 weeks until 26 weeks, and the incremental benefit of tadalafil beyond 26 weeks is unknown [see clinical studies (14.3)] .  administration of tadalafil to patients who are using any form of organic nitrate, either regularly and/or intermittently, is contraindicated. in clinical pharmacology studies, tadalafil was shown to potentiate the hypotensive effect of nitrates [see clinical pharmacology (12.2)] . tadalafil is contraindicated in patients with a known serious hypersensitivity to tadalafil (tadalafil tablets or adcirca® ). hypersensitivity reactions

United States - English - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - tadalafil (unii: 742sxx0ict) (tadalafil - unii:742sxx0ict) - tadalafil tablets are indicated for the treatment of erectile dysfunction (ed). tadalafil tablets are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (bph). tadalafil tablets are indicated for the treatment of ed and the signs and symptoms of bph (ed/bph). if tadalafil tablets are used with finasteride to initiate bph treatment, such use is recommended for up to 26 weeks because the incremental benefit of tadalafil tablets decreases from 4 weeks until 26 weeks, and the incremental benefit of tadalafil tablets beyond 26 weeks is unknown [see clinical studies ( 14.3)] . administration of tadalafil tablets to patients who are using any form of organic nitrate, either regularly and/or intermittently, is contraindicated. in clinical pharmacology studies, tadalafil was shown to potentiate the hypotensive effect of nitrates [see clinical pharmacology ( 12.2)] . tadalafil tablets are contraindicated in patients with a known serious hypersensitivity t

United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - tadalafil (unii: 742sxx0ict) (tadalafil - unii:742sxx0ict) - tadalafil tablets are indicated for the treatment of erectile dysfunction (ed). tadalafil tablets are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (bph). tadalafil tablets are indicated for the treatment of ed and the signs and symptoms of bph (ed/bph). if tadalafil is used with finasteride to initiate bph treatment, such use is recommended for up to 26 weeks because the incremental benefit of tadalafil decreases from 4 weeks until 26 weeks, and the incremental benefit of tadalafil beyond 26 weeks is unknown [see clinical studies (14.3)] .  administration of tadalafil to patients who are using any form of organic nitrate, either regularly and/or intermittently, is contraindicated. in clinical pharmacology studies, tadalafil was shown to potentiate the hypotensive effect of nitrates [see clinical pharmacology (12.2)] . tadalafil is contraindicated in patients with a known serious hypersensitivity to tadalafil (tadalafil tablets or adcirca® ). hypersensitivity reactions

United States - English - NLM (National Library of Medicine)

asclemed usa, inc. - tadalafil (unii: 742sxx0ict) (tadalafil - unii:742sxx0ict) - tadalafil tablets are indicated for the treatment of erectile dysfunction (ed). tadalafil tablets are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (bph). tadalafil tablets are indicated for the treatment of ed and the signs and symptoms of bph (ed/bph). if tadalafil tablets are used with finasteride to initiate bph treatment, such use is recommended for up to 26 weeks because the incremental benefit of tadalafil tablets decreases from 4 weeks until 26 weeks, and the incremental benefit of tadalafil tablets beyond 26 weeks is unknown [see clinical studies ( 14.3) ]. administration of tadalafil tablets to patients who are using any form of organic nitrate, either regularly and/or intermittently, is contraindicated. in clinical pharmacology studies, tadalafil tablets was shown to potentiate the hypotensive effect of nitrates [see clinical pharmacology ( 12.2)]. tadalafil tablets are contraindicated in patients with a known serious hypersensitivity

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - tadalafil (unii: 742sxx0ict) (tadalafil - unii:742sxx0ict) - tadalafil tablets are indicated for the treatment of erectile dysfunction (ed). tadalafil tablets are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (bph). tadalafil tablets are indicated for the treatment of ed and the signs and symptoms of bph (ed/bph). if tadalafil is used with finasteride to initiate bph treatment, such use is recommended for up to 26 weeks because the incremental benefit of tadalafil decreases from 4 weeks until 26 weeks, and the incremental benefit of tadalafil beyond 26 weeks is unknown [see clinical studies ( 14.3)] .  administration of tadalafil to patients who are using any form of organic nitrate, either regularly and/or intermittently, is contraindicated. in clinical pharmacology studies, tadalafil was shown to potentiate the hypotensive effect of nitrates [see clinical pharmacology ( 12.2)] . tadalafil is contraindicated in patients with a known serious hypersensitivity to tadalafil (tadalafil tablets or adcirca

United States - English - NLM (National Library of Medicine)

ajanta pharma usa inc. - tadalafil (unii: 742sxx0ict) (tadalafil - unii:742sxx0ict) - tadalafil tablets are indicated for the treatment of pulmonary arterial hypertension (pah) (who group 1) to improve exercise ability. studies establishing effectiveness included predominately patients with nyha functional class ii – iii symptoms and etiologies of idiopathic or heritable pah (61%) or pah associated with connective tissue diseases (23%). tadalafil tablet is contraindicated in patients who are using any form of organic nitrate, either regularly or intermittently. do not use nitrates within 48 hours of the last dose of tadalafil tablets. tadalafil tablets potentiates the hypotensive effect of nitrates. this potentiation is thought to result from the combined effects of nitrates and tadalafil tablets on the nitric oxide/cgmp pathway [see clinical pharmacology (12.2)] . coadministration of gc stimulator such as riociguat with tadalafil tablets is contraindicated. tadalafil tablets may potentiate the hypotensive effects of gc stimulators. tadalafil tablets are contraindicated in patients with a know

United States - English - NLM (National Library of Medicine)

aurobindo pharma limited - tadalafil (unii: 742sxx0ict) (tadalafil - unii:742sxx0ict) - tadalafil tablets are indicated for the treatment of pulmonary arterial hypertension (pah) (who group 1) to improve exercise ability. studies establishing effectiveness included predominately patients with nyha functional class ii to iii symptoms and etiologies of idiopathic or heritable pah (61%) or pah associated with connective tissue diseases (23%). tadalafil tablets are contraindicated in patients who are using any form of organic nitrate, either regularly or intermittently. do not use nitrates within 48 hours of the last dose of tadalafil tablets. tadalafil tablets potentiate the hypotensive effect of nitrates. this potentiation is thought to result from the combined effects of nitrates and tadalafil tablets on the nitric oxide/cgmp pathway [see clinical pharmacology (12.2)] . coadministration of gc stimulators such as riociguat with tadalafil tablets are contraindicated. tadalafil tablets may potentiate the hypotensive effects of gc stimulators. tadalafil tablets are contraindicated in patients with a